Friedrich, Nikolas http://orcid.org/0000-0003-0694-657X
Stiegeler, Emanuel
Glögl, Matthias
Lemmin, Thomas
Hansen, Simon
Kadelka, Claus http://orcid.org/0000-0002-5712-8529
Wu, Yufan
Ernst, Patrick http://orcid.org/0000-0001-6037-1856
Maliqi, Liridona
Foulkes, Caio
Morin, Mylène
Eroglu, Mustafa
Liechti, Thomas
Ivan, Branislav
Reinberg, Thomas
Schaefer, Jonas V.
Karakus, Umut
Ursprung, Stephan http://orcid.org/0000-0003-2476-178X
Mann, Axel
Rusert, Peter
Kouyos, Roger D. http://orcid.org/0000-0002-9220-8348
Robinson, John A. http://orcid.org/0000-0001-7857-8556
Günthard, Huldrych F. http://orcid.org/0000-0002-1142-6723
Plückthun, Andreas http://orcid.org/0000-0003-4191-5306
Trkola, Alexandra http://orcid.org/0000-0003-1013-876X
Article History
Received: 25 January 2021
Accepted: 3 November 2021
First Online: 18 November 2021
Competing interests
: AP is a co-founder and shareholder of Molecular Partners AG who are developing DARPins as therapeutics. HFG has been an advisor/consultant for Merck, Gilead Sciences, ViiV Healthcare and is a member of data safety monitoring boards outside of the submitted work. AT has been a consultant for Roche outside of the submitted work. All other authors declare no competing interests.